PMID-16602931 – Glucagon-Like Peptide-2 Biology
Estall JL, Drucker DJ. Glucagon-Like Peptide-2. Annu Rev Nutr. 2006;26:391-411.
Quick Reference
| Property | Value |
|---|---|
| PMID | 16602931 |
| DOI | 10.1146/annurev.nutr.26.061505.111223 |
| Year | 2006 |
| Journal | Annual Review of Nutrition |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (definitive review from the Drucker laboratory) |
| Peptide(s) Studied | GLP-2 |
Key Findings
- GLP-2 is a 33-amino-acid peptide co-secreted with GLP-1 from intestinal L-cells via post-translational processing of proglucagon
- The GLP-2 receptor (GLP-2R) is expressed predominantly in the gut (jejunum, ileum, colon) with limited expression in the CNS, lung, and lymph nodes
- GLP-2 stimulates crypt cell proliferation and inhibits apoptosis, leading to villus elongation, increased mucosal surface area, and enhanced absorptive capacity
- GLP-2 increases mesenteric blood flow via eNOS-dependent nitric oxide production, enhancing nutrient absorption
- GLP-2 upregulates expression of nutrient transporters (SGLT1, GLUT2, PEPT1) and digestive enzymes at the brush border
- Native GLP-2 has a short half-life (~7 minutes) due to DPP-4 cleavage; the Gly2 substitution in teduglutide confers DPP-4 resistance and extends half-life to ~2 hours
- GLP-2 has cytoprotective effects against mucosal injury from NSAIDs, chemotherapy, and inflammatory bowel disease models
Study Design
Comprehensive narrative review from Daniel Drucker's laboratory, which discovered the intestinotrophic properties of GLP-2 in 1996. Integrates molecular biology, receptor pharmacology, transgenic mouse studies, and early human clinical data to present the full biology of GLP-2 signaling.
Limitations
- Published before the pivotal Phase III teduglutide trial (Jeppesen 2012) and FDA approval, so clinical efficacy data is limited to Phase II studies
- GLP-2R signaling mechanisms were incompletely understood at the time; more recent work has clarified the role of ErbB ligands and IGF-1 as downstream mediators
- Does not address the potential oncogenic concern (intestinal trophic effects and colorectal neoplasia risk) that later became an important safety consideration
Clinical Relevance
This is the definitive early review of GLP-2 biology by the group that discovered its intestinotrophic properties. It provides the mechanistic foundation for understanding why teduglutide works in short bowel syndrome and identifies the key biological pathways (crypt proliferation, apoptosis inhibition, nutrient transporter upregulation, mesenteric blood flow) that underpin intestinal adaptation. Essential reference for the GLP-2 peptide profile and for Module 8 (GI & Gut Health Protocols).
Related
#research #narrative-review #glp-2 #evidence-level-V